Novel activators of aquaporin 2 membrane expression for the treatment of nephrogenic diabetes insipidus: less is more. Focus on "High-throughput chemical screening identifies AG-490 as a stimulator of aquaporin 2 membrane expression and urine concentration".

Abstract

nephrogenic diabetes insipidus (NDI) is a disease characterized by the production of very large quantities of dilute urine resulting from an inability of the kidney to respond to vasopressin ([9][1]). In the US, approximately 41,000 people are diagnosed with NDI each year. NDI can result from either